Frontiers in Oncology · 16 authors, 8 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This study analyzed 1,076 hepatocellular carcinoma patients from five public cohorts to create and validate a 24-gene prognostic signature based on pyroptosis-related genes. Patients with a high-risk score had significantly shorter overall survival than those with a low-risk score in training and validation cohorts.
This retrospective study analyzed clinical information and mRNA expression from 1,076 HCC patients across five public cohorts. Unsupervised clustering based on 40 pyroptosis-related genes identified three distinct pyroptotic clusters. A 24-gene prognostic signature was constructed using LASSO regression from differentially expressed genes between these clusters. The primary result was that a higher risk score was associated with significantly shorter overall survival. This finding was consistent in the training set (P<0.001; HR, 3.06) and the test set (P=0.008; HR, 1.61). The signature's predictive ability was further validated in a CPTAC cohort at both mRNA (P<0.001; HR, 2.99) and protein levels (P<0.001; HR, 2.97). Additionally, the low-risk group was linked to enrichment in angiogenesis pathways and showed a better response to sorafenib in an external cohort. Limitations include the retrospective design, use of public data from different platforms, and the need for prospective and experimental validation.
